Pharmahungary Group Founder & CEO attended the 6th Meeting of European Section and 7th Meeting of North American Section of the International Academy of Cardiovascular Sciences co-organized by the Serbian Association for Arteriosclerosis, Thrombosis and Vascular biology Research, conference title:
Cardiometabolic diseases: how new research may lead to new cardioprotective therapy. The prestigious event took place in Vrjnacka Banja, Serbia September 11-14, 2019 where Pharmahungary Group representative presented, Hidden cardiotoxicity – Paradigm change in cardiac safety testing in ischemic and comorbid conditions: an example of Rofecoxib.
– Novel Matrix Metalloproteinase-2 Inhibitors Decrease the Infarct Size in an In Vivo Model Of Acute Myocardial Infarction.
– Treatment of Acute Myocardial Infarction With Recanalization Accompanied with Ischemic Postconditioning: Study on Cardioprotection and Biomarkers